Trials / Recruiting
RecruitingNCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,200 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Detailed description
Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam. Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated. 1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation. 2. Pts. with hepatobiliary neoplasia 3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement 4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring
Conditions
Timeline
- Start date
- 2022-04-18
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2022-03-03
- Last updated
- 2026-01-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05264051. Inclusion in this directory is not an endorsement.